351 related articles for article (PubMed ID: 31227357)
1. Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.
Adrianzen Herrera D; Kornblum N; Derman O; Bachier-Rodriguez L; Sica RA; Shastri A; Janakiram M; Verma A; Braunschweig I; Mantzaris I
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):516-521. PubMed ID: 31227357
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
4. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
[TBL] [Abstract][Full Text] [Related]
5. Autologous hematopoietic cell transplantation for AML in first remission - An abandoned practice or promising approach?
Yeshurun M; Wolach O
Semin Hematol; 2019 Apr; 56(2):139-146. PubMed ID: 30926090
[TBL] [Abstract][Full Text] [Related]
6. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
[TBL] [Abstract][Full Text] [Related]
7. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
8. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.
Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640
[TBL] [Abstract][Full Text] [Related]
9. Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
Ock CY; Seo H; Kim DY; Min BJ; Park Y; Cheong HS; Kim HL; Song EY; Kim I; Yoon SS; Kim JH; Koh Y
Leuk Lymphoma; 2019 Jul; 60(7):1775-1781. PubMed ID: 30507323
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.
Mannis GN; Martin TG; Damon LE; Logan AC; Olin RL; Flanders MD; Ai WZ; Gaensler KM; Kaplan LD; Sayre PH; Smith CC; Wolf JL; Andreadis C
Leuk Lymphoma; 2016 Jul; 57(7):1560-6. PubMed ID: 26490487
[TBL] [Abstract][Full Text] [Related]
12. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B; Hospital MA; Zemmour C; Rey J; d'Incan E; Charbonnier A; Mohty B; Saillard C; Bonnet S; Collignon A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Ann Hematol; 2020 Apr; 99(4):773-780. PubMed ID: 32088745
[TBL] [Abstract][Full Text] [Related]
13. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
16. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
